Shares of Dr Reddy’s Laboratories Ltd were trading in the red and 1% lower on 17 August after its Bachupally, Hyderabad-based formulations manufacturing facility received four observations from the United States Food and Drug Administration (USFDA).  

The USFDA inspected Dr Reddy’s FTO-3 facility from August 6 to August 14, 2026, after which it issued a Form 483 containing four observations. A Form 483 is issued when FDA inspectors identify conditions that may represent violations of current Good Manufacturing Practice requirements. The observations are inspectional findings and do not represent a final determination by the regulator.

Dr Reddy’s has said it will address the observations within the stipulated timeline. The company is expected to submit corrective and preventive measures to the regulator to resolve the issues identified during the inspection.

The latest inspection is important because the FTO-3 plant is part of Dr Reddy’s formulations manufacturing network, which supplies medicines to regulated markets. Any significant regulatory action at a manufacturing facility can potentially affect product approvals, launches or supply from that site.

The development also follows other recent USFDA inspections involving Dr Reddy’s facilities. In June, the company’s Bachupally biologics facility received a Form 483 with seven observations following an inspection conducted from June 16 to June 25. The company had also faced five observations at the same site during a September 2025 inspection.

In July, Dr Reddy’s FTO-SEZ Process Unit-02 in Srikakulam received three observations following a combined pre-approval and GMP inspection.

For investors, the latest observations are likely to keep attention on the company’s compliance record and its ability to close regulatory issues without affecting production or future approvals. However, four Form 483 observations do not automatically mean that the facility will face a shutdown or regulatory ban.

At 1:20 pm, the shares of Dr Reddy’s Laboratories were trading 0.61% lower at Rs 1,192.60on the NSE.

Ready to invest like a pro? Tradz by EquityPandit app equips you with 100+ Free tools and knowledge you need to succeed. Download the Tradz by EquityPandit app and gain access to daily stock lists and insightful market analysis and much more!